Publications by authors named "A Pettinger"
Article Synopsis
- Reinfections of SARS-CoV-2 in the U.S. have become more common, especially during the Omicron variant period, rising from 2.7% during Delta to 28.8% in Omicron BQ.1/BQ.1.1.
- Hospitalizations and deaths linked to reinfections also increased significantly, going from 1.9% and 1.2% of COVID-19-related cases during Delta, to 17.0% and 12.3% during Omicron BQ.1/BQ.1.1.
- Younger adults (18-49 years) had higher rates of reinfections compared to older adults (≥50 years), and it's crucial to stay updated on vaccinations
Objectives: Systemic therapies for pancreatic neuroendocrine tumors (PNETs) are limited. The combination of bevacizumab and temsirolimus showed significant antitumor activity, but the single-agent activity of bevacizumab was unknown. We conducted a single-arm, phase II trial to evaluate the efficacy of bevacizumab in PNETs.
View Article and Find Full Text PDFImmunochemotherapy followed by autologous transplant (ASCT) in CALGB/Alliance 59909 achieved a median progression-free survival (PFS) in mantle cell lymphoma (MCL) of 5 years, but late recurrences occurred. We evaluated tolerability and efficacy of adding post-transplant bortezomib consolidation (BC) or maintenance (BM) to this regimen in CALGB/Alliance 50403, a randomized phase II trial. Following augmented-dose R-CHOP/ methotrexate, high-dose cytarabine-based stem cell mobilization, cyclophosphamide/carmustine/etoposide (CBV) autotransplant, and rituximab, patients were randomized to BC (1.
View Article and Find Full Text PDFThe introduction of the anti-CD20 antibody rituximab in combination with chemotherapy (R-chemo) has improved the prognosis of patients with follicular lymphoma (FL). During the last decade, the addition of a maintenance treatment with rituximab (MR) after R-chemo has been tested with the hope of further improving the outcome of these patients. Using 2 independent population-based cohorts, we investigated the effect of up-front MR on time related end points as well as the risk of histological transformation (HT).
View Article and Find Full Text PDFPurpose This multinational study evaluated the antitumor activity of nivolumab in nasopharyngeal carcinoma (NPC). Tumor and plasma-based biomarkers were investigated in an exploratory analysis. Patients and Methods Patients with multiply pretreated recurrent or metastatic NPC were treated with nivolumab until disease progression.
View Article and Find Full Text PDF